Queen Mary Innovation

Queen Mary Innovation serves as the technology transfer arm of Queen Mary University of London. It protects and licenses intellectual property arising from university research across life sciences, healthcare, engineering, materials science and more. QMI builds sustainable enterprises—spinning out nearly three new companies per year—and licenses innovations to industry partners globally. Its pipeline features digital health tools for cardiovascular disease management and dementia risk prediction; novel diagnostics such as real-time nanoscale biochips; therapeutics including peptide therapies for blinding eye conditions; advanced biomaterials like synthetic heart valves; AI-enabled healthcare solutions; and unique platforms such as TREX for mapping RNA-protein interactions. The company’s impact spans both economic value creation through commercialization and social benefit by supporting NHS innovation adoption locally.